PMID- 21523726
OWN - NLM
STAT- MEDLINE
DCOM- 20110614
LR  - 20181201
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 117
IP  - 10
DP  - 2011 May 15
TI  - Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with 
      recurrent multiple myeloma treated with lenalidomide and dexamethasone.
PG  - 2136-44
LID - 10.1002/cncr.25775 [doi]
AB  - BACKGROUND: In the era of novel agents such as lenalidomide and bortezomib, risk 
      stratification by chromosomal abnormalities may enable a more rational selection 
      of therapeutic approaches in patients with multiple myeloma (MM). METHODS: The 
      authors analyzed the prognostic value of deletion del(13q14), del(17p13), +1q21, 
      translocation t(4;14), t(11;14), and t(14;16) by fluorescence in situ 
      hybridization (FISH) in a series of 92 patients with recurrent MM who were 
      treated with lenalidomide and dexamethasone (len/dex) at the study center. 
      RESULTS: Patients carrying del(13q14) or t(14;16) were found to have a shorter 
      median time to disease progression (TTP) of 5.1 months (vs 14.4 months; P = .009) 
      and 2.0 months (vs 10.5 months; P <.001), respectively. However, no effect on TTP 
      was observed in patients harboring del(13q14) as an exclusive chromosomal 
      aberration without the concomitant presence of t(4;14) or del(17p13). The median 
      overall survival (OS) for patients with del(17p13) or +1q21 was 6.7 months (P = 
      .002) and 8.3 months (P < .001), respectively, whereas the median OS for patients 
      carrying none of these abnormalities was not reached. Multivariate analysis 
      revealed that the effects of del(17p13) and +1q21 on OS were independent of 
      patient age as well as the type and number of regimens administered before 
      len/dex. CONCLUSIONS: The results of the current study suggest that the 
      prognostic significance of t(4;14) may be ameliorated or eliminated in patients 
      treated with len/dex, whereas the presence of del(17p13) or +1q21 is still 
      associated with a dismal OS. The presence of t(11;14) and del(13q14) as exclusive 
      chromosomal aberrations indicates no impact on outcome. Because of its rarity in 
      MM, a confirmation of the prognostic role of the t(14;16) aberration is still 
      pending.
CI  - 2010 American Cancer Society.
FAU - Klein, Ulrike
AU  - Klein U
AD  - Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
FAU - Jauch, Anna
AU  - Jauch A
FAU - Hielscher, Thomas
AU  - Hielscher T
FAU - Hillengass, Jens
AU  - Hillengass J
FAU - Raab, Marc S
AU  - Raab MS
FAU - Seckinger, Anja
AU  - Seckinger A
FAU - Hose, Dirk
AU  - Hose D
FAU - Ho, Anthony D
AU  - Ho AD
FAU - Goldschmidt, Hartmut
AU  - Goldschmidt H
FAU - Neben, Kai
AU  - Neben K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101204
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - *Chromosome Aberrations
MH  - Chromosome Deletion
MH  - Chromosomes, Human, Pair 1
MH  - Chromosomes, Human, Pair 14
MH  - Chromosomes, Human, Pair 17
MH  - Dexamethasone/*administration & dosage
MH  - Female
MH  - Humans
MH  - Lenalidomide
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy
MH  - Prognosis
MH  - Recurrence
MH  - Thalidomide/administration & dosage/*analogs & derivatives
MH  - Translocation, Genetic
EDAT- 2011/04/28 06:00
MHDA- 2011/06/15 06:00
CRDT- 2011/04/28 06:00
PHST- 2010/05/21 00:00 [received]
PHST- 2010/08/29 00:00 [revised]
PHST- 2010/10/05 00:00 [accepted]
PHST- 2011/04/28 06:00 [entrez]
PHST- 2011/04/28 06:00 [pubmed]
PHST- 2011/06/15 06:00 [medline]
AID - 10.1002/cncr.25775 [doi]
PST - ppublish
SO  - Cancer. 2011 May 15;117(10):2136-44. doi: 10.1002/cncr.25775. Epub 2010 Dec 4.